Holen Sie sich die Stockscreener-App
1.31
0.77%
0.01
Handel nachbörslich:
1.29
-0.02
-1.53%
Longeveron Inc Aktie (LGVN) Neueste Nachrichten
Transcript : Longeveron Inc.Shareholder/Analyst Call - MarketScreener
Jane Street Group LLC Acquires New Shares in Longeveron Inc. (NASDAQ:LGVN) - Defense World
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - The Manila Times
Longeveron Inc. CEO Wa’el Hashad to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - Nasdaq
Exclusive Look: Longeveron CEO Reveals Latest Neuro Therapy Developments at Major Healthcare Conference - Stock Titan
18,190 Shares in Longeveron Inc. (NASDAQ:LGVN) Bought by Northern Trust Corp - Defense World
Director’s Major Stock Sale Shakes Up Longeveron! - TipRanks
Here's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash Wisely - Yahoo Finance
Q2 Earnings Estimate for Longeveron Issued By HC Wainwright - Defense World
Longeveron Inc. to Explore Partnership Opportunities for Alzheimer’s Stem Cell Therapy Program at BIO International Convention - Nasdaq
Longeveron® to Attend BIO International Convention 2025 - Yahoo Finance
Is Palantir Stock a Buy at All-Time Highs? - The Globe and Mail
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient - GlobeNewswire
Longeveron Inc. Named Top 40 Semifinalist in XPRIZE Healthspan Competition for Stem Cell Therapy Evaluation in Alzheimer’s Disease and HLHS - Nasdaq
Longeveron (LGVN) Projected to Post Earnings on Tuesday - Defense World
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update - BioSpace
Longeveron Q1 2025 slides: promising clinical data amid financial headwinds By Investing.com - Investing.com India
Longeveron Reports Q1 2025 Progress and Financials - TipRanks
Earnings call transcript: Longeveron Reports Q1 2025 Results Amid Revenue Decline - Investing.com Canada
Longeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Contineum Therapeutics (NASDAQ:CTNM) versus Longeveron (NASDAQ:LGVN) Financial Survey - Defense World
Longeveron Earnings Preview: Latest Updates on Cellular Therapy Pipeline Coming May 8 - Stock Titan
Longeveron Inc. to Report Q1 2025 Financial Results and Business Update on May 8 - Nasdaq
Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - The Manila Times
Longeveron Re-approves Cash-to-Equity Program Strategy - TipRanks
Press Release Distribution & PR Platform - ACCESS Newswire
Longeveron® Issues Letter to Shareholders Highlighting - GlobeNewswire
FDA Green Lights Longeveron's Fast-Track Strategy: Key Trials Near Completion for $10B+ Markets - Stock Titan
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update - Seeking Alpha
Where Will Palantir Stock Be in 1 Year? - The Globe and Mail
Longeveron Files $70 Million Mixed Shelf - MarketScreener
Longeveron Inc Files For Mixed Shelf Of Up To $70 MillionSEC Filing - MarketScreener
Stem Cell Treatment Improves Alzheimer's Symptoms - Newsmax
Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright - Defense World
Pharma company behind Alzheimer’s treatment closer to FDA approval - The Business Journals
FDA aligns with Longeveron on Alzheimer’s therapy trial By Investing.com - Investing.com South Africa
FDA aligns with Longeveron on Alzheimer’s therapy trial - Investing.com
Longeveron announces outcome of Type B meeting with FDA on Lomecel-B - TipRanks
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease - The Manila Times
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease - TradingView
FDA Clears BLA Pathway for Longeveron's Alzheimer's Cell Therapy | LGVN Stock News - Stock Titan
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire
Longeveron's Cell Therapy Lomecel-B Improves Cognitive Function in Mild Alzheimer Disease - CGTLive®
Laromestrocel shows promise in Alzheimer’s trial By Investing.com - Investing.com Australia
Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B(TM)) In Alzheimer'S Disease - Marketscreener.com
Laromestrocel shows promise in Alzheimer’s trial - Investing.com India
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease - The Manila Times
Longeveron announces publication of results of Phase 2a trial of Lomecel-B - TipRanks
Longeveron Inc. Reports Positive Phase 2a Results for Laromestrocel (Lomecel-B™) in Mild Alzheimer’s Disease Treatment - Nasdaq
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):